MedTrace Logo

Treating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg

NCT07705893 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-07-30

No results posted yet for this study

Summary

The objective of this study is to evaluate whether twice-daily use of Tyrvaya improves contact lens comfort in contact lens wearers.

Conditions

  • Dry Eye

Interventions

DRUG

Tyrvaya

Tyrvaya (varenicline solution 0.03 mg) is a nasal spray, which is dosed twice daily, that is indicated for treating signs and symptoms of dry eye disease (DED )This dropless ocular surface sparing dosing pattern is ideal for the busy CL patient because they can easily administer Tyrvaya twice a day while keeping their contact lens on.

Sponsors & Collaborators

  • Viatris Inc.

    collaborator INDUSTRY

  • Ocular Aesthetics, LLC dba Ocular Clinical Trials

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-28
Primary Completion
2026-12-31
Completion
2027-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07705893 on ClinicalTrials.gov